Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Cash from Operating Activities
Samsung Biologics Co Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Cash from Operating Activities
₩1.7T
|
CAGR 3-Years
102%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Cash from Operating Activities
-₩11B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Cash from Operating Activities
₩5.2B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cash from Operating Activities
₩1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cash from Operating Activities
-₩3.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cash from Operating Activities
-₩62.2B
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-26%
|
See Also
What is Samsung Biologics Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.7T
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Cash from Operating Activities amounts to 1.7T KRW.
What is Samsung Biologics Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
102%
Over the last year, the Cash from Operating Activities growth was 75%. The average annual Cash from Operating Activities growth rates for Samsung Biologics Co Ltd have been 102% over the past three years .